絞り込み

16640

広告

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

著者 Bone HG , Wagman RB , Brandi ML , Brown JP , Chapurlat R , Cummings SR , Czerwiński E , Fahrleitner-Pammer A , Kendler DL , Lippuner K , Reginster JY , Roux C , Malouf J , Bradley MN , Daizadeh NS , Wang A , Dakin P , Pannacciulli N , Dempster DW , Papapo
Lancet Diabetes Endocrinol.2017 May 22 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1,578view , 0users)

Full Text Sources

Medical

Other Literature Sources

Long-term safety and efficacy of osteoporosis treatment are important because of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of denosumab, which is widely used for the treatment of postmenopausal women with osteoporosis.
PMID: 28546097 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード